Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/COPD.S85976 http://scihub22266oqcxt.onion/10.2147/COPD.S85976 C4765947!4765947!26937185     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Chron+Obstruct+Pulmon+Dis 2016 ; 11 (Spec Iss): 3-12 Nephropedia Template TP {{tp|p=26937185|t=2016. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1 |pdf=|usr=}}{{26937185}} gab.com Text Diagnosis, assessment, and phenotyping of COPD: beyond FEV1 JO: Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=26937185 #FOAvip COPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and ?frequent exacerbators?. Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as ?asthma COPD overlap syndrome?. Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics. Twit Text FOAVip Diagnosis, assessment, and phenotyping of COPD: beyond FEV1 ????Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=26937185 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26937185 #FOAvip English Wikipedia <ref>{{Cite pmid|26937185}}</ref> Diagnosis, assessment, and phenotyping of COPD: beyond FEV1 #MMPMID26937185 Lange P; Halpin DM; O?Donnell DE; MacNee W Int J Chron Obstruct Pulmon Dis 2016[]; 11 (Spec Iss): 3-12 PMID26937185show ga COPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and ?frequent exacerbators?. Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as ?asthma COPD overlap syndrome?. Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics. äDiagnosis, assessment, and phenotyping of COPD: beyond FEV1 (epmc).pdf DeepDyve Pubget Overpricing